Advertisement

 

 

Co-administration of a konjac-based fibre blend and American ginseng (Panax quinquefolius L.) on glycaemic control and serum lipids in type 2 diabetes: a randomized controlled, cross-over clinical trial.

Co-administration of a konjac-based fibre blend and American ginseng (Panax quinquefolius L.) on glycaemic control and serum lipids in type 2 diabetes: a randomized controlled, cross-over clinical trial.
Author Information (click to view)

Jenkins AL, Morgan LM, Bishop J, Jovanovski E, Jenkins DJA, Vuksan V,


Jenkins AL, Morgan LM, Bishop J, Jovanovski E, Jenkins DJA, Vuksan V, (click to view)

Jenkins AL, Morgan LM, Bishop J, Jovanovski E, Jenkins DJA, Vuksan V,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

European journal of nutrition 2017 07 07() doi 10.1007/s00394-017-1496-x
Abstract
PURPOSE
Use of polypharmacy in the treatment of diabetes is the norm; nonetheless, optimal control is often not achieved. Konjac-glucomannan-based fibre blend (KGB) and American ginseng (AG) have individually been shown to improve glycaemia and CVD risk factors in type 2 diabetes. The aim of this study was to determine whether co-administration of KGB and AG could improve diabetes control beyond conventional treatment.

METHOD
Thirty-nine participants with type 2 diabetes (6.5 > A1c < 8.4%) were enrolled between January 2002 and May 2003 at the Risk Factor Modification Centre at St Michaels Hospital in a randomized, placebo-controlled, crossover trial with each intervention lasting 12-weeks. Medications, diet and lifestyle were kept constant. Interventions consisted of 6 g of fibre from KGB together with 3 g of AG (KGB and AG) or wheat bran-based, fibre-matched control. Primary endpoint was the difference in HbA1c levels at week 12. RESULTS
Thirty participants (18M:12F; age: 64 ± 7 years; BMI: 28 ± 5 kg/m(2); HbA1c: 7.0 ± 1.0%) completed the study, and consumed 5.5 and 4.9 g/day of fibre from KGB and wheat bran control, respectively, and 2.7 g/day of AG. At week 12, HbA1c levels were 0.31% lower on the KGB and AG compared to control (p = 0.011). Mean (±SEM) plasma lipids decreased on the KGB and AG vs control by 8.3 ± 3.1% in LDL-C (p = 0.002), 7.5 ± 2.4% in non-HDL-C (p = 0.013), 5.7 ± 1.9% in total-C (p = 0.012), 4.1 ± 2.1% in total-C:HDL-C ratio (p = 0.042), 9.0 ± 2.3% in ApoB (p = 0.0005) and 14.6 ± 4.2% in ApoB:ApoA1 ratio (p = 0.049).

CONCLUSIONS
Co-administration of KGB and AG increases the effectiveness of conventional therapy through a moderate but clinically meaningful reduction in HbA1c and lipid concentrations over 12 weeks in patients with type 2 diabetes.

CLINICAL TRIALS REGISTRATION
NCT02806349 ( https://clinicaltrials.gov/ ).

Submit a Comment

Your email address will not be published. Required fields are marked *

fourteen − 2 =

[ HIDE/SHOW ]